Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients
Overview
Pathology
Authors
Affiliations
BACKGROUND The aim of this study was to observe apolipoprotein M (ApoM) level in obese patients and to explore its correlation with inflammatory factors. MATERIAL AND METHODS A total number of 96 participants were recruited and divided into 2 groups: the control group (or healthy group) whose participants had normal body weight (n=58), and the obese group with all its participants diagnosed with obesity (n=38). Data on blood pressure, body weight, height, body mass index, diastolic function of brachial artery endothelium, fasting venous blood glucose, blood lipids, plasmatic ApoM, interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), fasting insulin, and adiponectin levels were collected for both groups. RESULTS In the obese group, the levels of plasmatic ApoM, high-density lipoprotein cholesterol (HDL-C), and plasmatic adiponectin were significantly (p<0.05) decreased compared to the control group, and the levels of IL-6, TNF-α, CRP, and fasting insulin were significantly increased (p<0.05) compared to the control group. For the obese group, plasmatic ApoM level was positively correlated with HDL-C level and negatively correlated with levels of IL-6, TNF-α, CRP, insulin, and insulin resistance index. However, no significant correlations were revealed between plasmatic ApoM and the diastolic function of brachial artery endothelium, adiponectin level, blood pressure, and blood glucose level. CONCLUSIONS Obese patients showed significantly lower plasmatic ApoM levels than people with normal body weight, and ApoM level showed a strong correlation with CRP, TNF-α, and IL-6 levels, which indicated that ApoM might be regulated by these inflammatory factors.
Pammer A, Obermayer A, Stadler J, Pferschy P, Tripolt N, Habisch H Cardiovasc Diabetol. 2024; 23(1):339.
PMID: 39267053 PMC: 11395628. DOI: 10.1186/s12933-024-02426-5.
Frances L, Croyal M, Ruidavets J, Maraninchi M, Combes G, Raffin J Int J Obes (Lond). 2024; 48(7):973-980.
PMID: 38491190 PMC: 11216985. DOI: 10.1038/s41366-024-01510-w.
Bialecka M, Dziedziejko V, Safranow K, Krzystolik A, Marcinowska Z, Chlubek D Diagnostics (Basel). 2024; 14(4).
PMID: 38396488 PMC: 10887573. DOI: 10.3390/diagnostics14040449.
Butler A, Moin A, Reiner Z, Sathyapalan T, Jamialahmadi T, Sahebkar A Front Endocrinol (Lausanne). 2023; 14:1117761.
PMID: 37181037 PMC: 10171110. DOI: 10.3389/fendo.2023.1117761.
An association between adropin hormone and total testosterone in obese men: a case-control study.
Muhammed A, Eid R, Mohammed W, Abdel-Fadeil M BMC Endocr Disord. 2022; 22(1):192.
PMID: 35897011 PMC: 9327160. DOI: 10.1186/s12902-022-01102-7.